These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Gene Therapy for the Treatment of Primary Immune Deficiencies. Kuo CY; Kohn DB Curr Allergy Asthma Rep; 2016 May; 16(5):39. PubMed ID: 27056559 [TBL] [Abstract][Full Text] [Related]
8. Perspectives of gene therapy for primary immunodeficiencies. Chinen J; Puck JM Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):523-7. PubMed ID: 15640693 [TBL] [Abstract][Full Text] [Related]
9. Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy. Trifari S; Marangoni F; Scaramuzza S; Aiuti A; Roncarolo MG; Dupré L Expert Rev Clin Immunol; 2007 Mar; 3(2):205-15. PubMed ID: 20477109 [TBL] [Abstract][Full Text] [Related]
10. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783 [TBL] [Abstract][Full Text] [Related]
11. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446 [TBL] [Abstract][Full Text] [Related]
12. Gene therapy for primary immune deficiencies: a Canadian perspective. Xu X; Tailor CS; Grunebaum E Allergy Asthma Clin Immunol; 2017; 13():14. PubMed ID: 28261277 [TBL] [Abstract][Full Text] [Related]
13. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug. Ferrua F; Aiuti A Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159 [TBL] [Abstract][Full Text] [Related]
14. Progress and prospects: gene therapy for inherited immunodeficiencies. Qasim W; Gaspar HB; Thrasher AJ Gene Ther; 2009 Nov; 16(11):1285-91. PubMed ID: 19776764 [TBL] [Abstract][Full Text] [Related]
15. Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency. Montiel-Equihua CA; Thrasher AJ; Gaspar HB Stem Cells Cloning; 2009 Dec; 3():1-12. PubMed ID: 24198507 [TBL] [Abstract][Full Text] [Related]
16. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments]. Smogorzewska EM; Weinberg KI; Kohn DB Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167 [TBL] [Abstract][Full Text] [Related]
17. Genetic Engineering and Manufacturing of Hematopoietic Stem Cells. Wang X; Rivière I Mol Ther Methods Clin Dev; 2017 Jun; 5():96-105. PubMed ID: 28480310 [TBL] [Abstract][Full Text] [Related]
18. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992. Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188 [TBL] [Abstract][Full Text] [Related]
19. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365 [TBL] [Abstract][Full Text] [Related]
20. Successes and risks of gene therapy in primary immunodeficiencies. Chinen J; Puck JM J Allergy Clin Immunol; 2004 Apr; 113(4):595-603; quiz 604. PubMed ID: 15100660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]